Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 173

Results For "PPL"

3049 News Found

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22
News | January 12, 2023

HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22

The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management


Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
News | January 11, 2023

Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions


Sirio Pharma successfully completes acquisition of Best Formulations
News | January 10, 2023

Sirio Pharma successfully completes acquisition of Best Formulations

With more than 35 years of experience, Best Formulations is the largest manufacturer of plant-based softgels in the United States, with newly expanded capabilities for nutritional gummies and personal care


NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme
Policy | January 10, 2023

NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme

The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023
Policy | January 05, 2023

Mandaviya chairs a high-level meeting to review elimination of Kala-Azar by 2023

The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.


IIT Kanpur and Apollo Hospitals join hands for research collaboration
News | January 04, 2023

IIT Kanpur and Apollo Hospitals join hands for research collaboration

The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology